TABLE 2.
Cox Proportional Hazards Model of Overall Survival of Molecular Profiling of Breast Cancer Study Participants Assigned to the Neoadjuvant Arm, According to RCB
| Variable | No. | Unadjusted Cox | Adjusted Cox | ||||
|---|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | P | Hazard Ratio | 95% | P | ||
| RCB | |||||||
| RCB 0 | 53 | reference | reference | ||||
| RCB I | 28 | 1.40 | 0.4 to 5.3 | .608 | 2.15 | 0.5 to 8.0 | .272 |
| RCB II | 118 | 3.00 | 1.2 to 7.7 | .023* | 3.69 | 1.4 to 9.7 | .008** |
| RCB III | 115 | 5.40 | 2.1 to 13 | <.001*** | 8.19 | 3.1 to 21 | <.001*** |
| Age | 314 | 1.00 | 0.9 to 1.0 | .844 | 0.99 | 0.9 to 1.0 | .998 |
| Menopausal status | |||||||
| Premenopausal | 154 | reference | reference | ||||
| Perimenopausal | 4 | <0.001 | 0.0 to Inf | .995 | <0.001 | 0.0 to Inf | .995 |
| Postmenopausal | 156 | 0.82 | 0.5 to 1.3 | .373 | 0.83 | 0.4 to 1.6 | .594 |
| Grade | |||||||
| Low | 24 | reference | reference | ||||
| Intermediate | 163 | 2.60 | 0.8 to 8.4 | .110 | 3.72 | 1.1 to 12 | .038* |
| High | 127 | 3.30 | 1.0 to 10 | .048* | 3.82 | 1.0 to 13 | .041* |
| Country | |||||||
| Argentina | 95 | reference | reference | ||||
| Brazil | 50 | 1.12 | 0.6 to 2.1 | .726 | 1.31 | 0.6 to 2.8 | .489 |
| Chile | 54 | 1.16 | 0.6 to 2.1 | .638 | 1.39 | 0.7 to 2.6 | .313 |
| Mexico | 95 | 0.86 | 0.5 to 1.5 | .605 | 0.69 | 0.4 to 1.3 | .255 |
| Uruguay | 20 | 0.86 | 0.3 to 2.2 | .750 | 0.79 | 0.3 to 2.2 | .662 |
| cT | |||||||
| T1 | 4 | reference | reference | ||||
| T2 | 83 | 0.61 | 0.1 to 4.6 | .636 | 0.56 | 0.1 to 4.8 | .592 |
| T3 | 165 | 0.96 | 0.3 to 7.0 | .971 | 0.85 | 0.1 to 7.0 | .879 |
| T4 | 62 | 1.10 | 0.1 to 8.2 | .923 | 0.95 | 0.1 to 8.2 | .961 |
| cN | |||||||
| N0 | 57 | reference | reference | ||||
| N1 | 182 | 1.20 | 0.6 to 2.3 | .527 | 0.76 | 0.4 to 1.5 | .430 |
| N2 | 69 | 2.30 | 1.2 to 4.6 | .015* | 1.23 | 0.6 to 2.6 | .595 |
| N3 | 6 | 1.80 | 0.4 to 8.2 | .425 | 0.98 | 0.2 to 5.0 | .983 |
| IHC | |||||||
| HR+ HER2– Ki67-low | 71 | reference | reference | ||||
| HR+ HER2– Ki67-high | 92 | 1.50 | 0.8 to 3.0 | .247 | 1.46 | 0.7 to 3.1 | .321 |
| HR+ HER2+ | 37 | 1.60 | 0.7 to 3.7 | .313 | 2.13 | 0.9 to 5.2 | .099 |
| HR– HER2+ | 39 | 1.20 | 0.5 to 3.0 | .746 | 1.81 | 0.6 to 5.0 | .255 |
| HR– HER2– | 75 | 3.80 | 1.9 to 7.4 | <.001*** | 5.12 | 2.5 to 10 | <.001*** |
NOTE. Hazard ratios of univariate and multivariate models are shown with their corresponding 95% CIs and P values. Models considered RCB as the main predictor, and the rest of the variables as potential or known confounders or covariables. Analyses were performed only with the participants with no missing values in any of the variables involved. The asterisk denotes the level of statistical significance for the hazard ratio *P < .05, **P < .01, ***P < .001.
Abbreviations: cN, clinical nodal status; cT, clinical T stage; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; RCB, residual cancer burden.